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Abstract
Objectives: It has been suggested that inhibin secretion is altered in women with the polycystic ovary syndrome
(PCOS). However, the contribution of a preceding luteal phase has not been taken into account. The aim of the
present study was to investigate whether progesterone in the context of a simulated luteal phase affects basal and
FSH-induced inhibin secretion in women with PCOS and elevated LH.
Methods: Ten women with PCOS and 8 normally cycling women participated in an experimental procedure (Exp)
involving the administration of a single injection of recombinant FSH (450 IU sc). In the women with PCOS, the
procedure was performed before (Exp 1) and after a 20-day treatment with progesterone (Exp 2), while in the
normal women on day 2 of the cycle (Exp 3). Inhibin A and B levels were measured in blood samples taken before
and 24 hours after the FSH injection.
Results: Basal LH levels were significantly higher and inhibin A levels were significantly lower in the PCOS group
compared to the control group, while inhibin B levels were comparable in the two groups. In the PCOS group,
after treatment with progesterone inhibin A and LH but not inhibin B levels decreased significantly (p < 0.05). After
the FSH injection, inhibin A and B levels increased significantly in the women with PCOS (Exp 1 and Exp 2) but not
in the control women (Exp 3).
Conclusions: In women with PCOS, as compared to control women, the dissimilar pattern of inhibin A and inhibin
B secretion in response to FSH appears to be independent of a preceding simulated luteal phase. It is possible that
compared to normal ovaries, the PCOS ovaries are less sensitive to endogenous LH regarding inhibin A secretion
and more sensitive to exogenous FSH stimulation in terms of inhibin A and inhibin B secretion.
Background
Data regarding inhibin levels in the circulation of women
with polycystic ovary syndrome (PCOS) are conflicting.
In particular, when compared to controls inhibin B con-
centrations have been found to be either increased [1,2]
or similar [3-9]. On the other hand, most studies [3,7,10],
but not all [2] have suggested that inhibin A levels are
lower in women with PCOS than in control women. It
has been suggested that in normal women, the intercycle
rise of FSH is responsible for the increased secretion of
inhibin B coming from the small antral follicles in the
early follicular phase, while the midcycle LH increase sti-
mulates inhibin A secretion coming from the pre-ovula-
tory follicle [11]. However, in women with PCOS, the
role of gonadotrophins in the regulation of inhibin secre-
tion is less clear and is based on data mainly derived
from experiments involving the exogenous administra-
tion of FSH [2,9,12]. Even so, the data are scanty showing
differences between PCOS and controls regarding the
pattern of inhibin B secretion in response to a single or
multiple doses of FSH [2,9,12]. On the other hand, inhi-
bin A levels showed a similar pattern of increase in
PCOS and in control women [2,12]. * Correspondence: messinis@med.uth.gr
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normally cycling women regarding the inhibin response
to FSH has not yet been defined. Previous experiments
investigating the dynamic response of inhibin to a single
dose of FSH were performed in PCOS women at a ran-
dom day or after exclusion of recent ovulation, i.e. at a
time far beyond the luteal phase, while in normally
cycling women in the early to mid follicular phase
[9,12]. Therefore, it is not known if the above differ-
ences in inhibin secretion are related to the lack of pro-
gesterone in PCOS due to chronic anovulation. It has
been shown that exogenous progesterone reduces ele-
vated circulating LH levels in women with PCOS [13],
while LH may affect inhibin A secretion in normally
cycling women [11].
The present study was undertaken to test the hypoth-
esis if the distinct pattern of inhibin secretion under the
stimulation by FSH in womenw i t hP C O Sr e s u l t sf r o m
the lack of the luteal phase. The present experiments
were performed in women with PCOS and elevated LH
after the exogenous administration of progesterone, as a
surrogate of previous ovulation and luteal phase
function.
Methods
Subjects
Ten women with PCOS (aged 24.5 ± 2.1 years) and 8
women with normal menstrual cycles (aged 31.5 ± 1.0
years), which served as controls, volunteered for the
study and gave written informed consent. The body
mass index (BMI) of women with PCOS was 26.0 ± 2.5
kg/m
2 and that of the normal women 21.0 ± 1.1 kg/m
2.
The difference was not significant. Institutional Review
Board approval of the study was obtained. Polycystic
ovary syndrome was diagnosed according to the revised
2003 criteria [14]. In particular, all women had polycys-
tic ovaries by ultrasound and amenorrhoea or oligome-
norrhoea. In addition to that, all women with PCOS had
elevated LH with LH to FSH ratio greater than 2. Exclu-
sion criteria were normal LH, normal cycles, obesity
(BMI > 30 kg/m
2) and any medical or hormonal treat-
ment during the last six months before the women
entered the study. The women with PCOS were
recruited at an outpatient clinic of gynaecological endo-
crinology. A total of 35 women with PCOS were
screened and 10 were finally included fulfilling the
above criteria. Sample size calculation was based on the
data of a previous study [12].
All women participated in the same experimental pro-
cedure (Exp) involving the sc injection of a single dose
450 IU recombinant FSH (Puregon 150 IU; Organon Hel-
las, Athens, Greece) (0900 h). The dose of exogenous
FSH was based on our previous studies [15-17]. The
women with PCOS were investigated in two experimental
procedures, i.e. before (Exp 1) and after a 20-day treat-
ment with progesterone (Exp 2). The Exp 1 was per-
formed on a random day at least 15-20 days after a
spontaneous period and after ovarian quiescence was
confirmed by ultrasonography and serum estradiol and
progesterone measurement. The administration of pro-
gesterone started the day after the end of the Exp 1. The
Exp 2 was performed on the day following the end of the
20-day treatment with progesterone (Utrogestan cap-
sules, 100 mg; Faran, Athens, Greece) at the oral dose of
300 mg/day. Although the length of the normal luteal
phase is no more than 16 days [18], in the present study
progesterone was given to the PCOS women for 20 days
in order to enhance the progestational effect in these
patients who only occasionally are exposed to this steroid
due to chronic anovulation. In the normally cycling
women (Exp 3), the dose of 450 IU FSH was given sc on
day 2 of the cycle.
In each experiment, two blood samples were taken,
one before and a second sample 24 hours after the FSH
injection. All blood samples were centrifuged at 1000 g
for 15 min and serum was stored at -20°C until assayed.
Serum FSH, LH, inhibin A and inhibin B were measured
in all blood samples.
Assays
Measurement of FSH and LH in serum was performed
using a Chemiluminescent Microparticle Immunoassay
(Architect FSH and Architect LH respectively; Abbott
Laboratories, Illinois, USA). The results are expressed as
IU/l for FSH and LH. Inhibin A and inhibin B were
measured using an enzyme-linked immunosorbent assay
(Inhibin A, Active
® ELISA and Inhibin B, Active
®
ELISA, Diagnostic Systems Laboratories, Texas, USA).
The results are expressed as pg/ml. The lower limits of
detection for FSH, LH, inhibin A and inhibin B were
0.05 IU/l, 0.07 IU/l, 1 pg/ml and 7 pg/ml respectively.
Inter- and intra-assay coefficients of variation were 3.1
and 3.4%, 2.0 and 3.4%, 7.8 and 3.6% and 7.2 and 5.6%
respectively.
Statistical analysis
H o r m o n ev a l u e sw e r en o r m a l l yd i s t r i b u t e d( o n es a m p l e
Kolmogorov-Smirnov test). Statistical analysis was per-
formed by paired t-test, one-way analysis of variance
(ANOVA) followed by Bonferroni post hoc testing. All
values are expressed as means ± SEM. An a-level of
0.05 was used to determine statistical significance. The
statistical software package used was SPSS 15.0.
Results
Except inhibin values, hormone values following the FSH
injection have been reported in more details elsewhere
[19]. Serum estradiol and progesterone concentrations
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[19]. Before the FSH injection, serum FSH levels did not
differ significantly between the three experiments (Figure
1A). Following the FSH injection, serum FSH concentra-
tions increased significantly in all three experiments (p <
0.05), with no significant difference between them (Figure
1A). Serum LH levels were before the FSH injection sig-
nificantly higher in the women with PCOS (Exp 1) as
compared to the control women (Exp 3) (p < 0.05) but
treatment with progesterone reduced significantly the LH
values to the normal range (Exp 2, Figure 1B). After the
FSH injection, LH values decreased in all experiments (p
< 0.05), that in the PCOS women were still significantly
higher than in the controls (p < 0.05) (Figure 1B). At the
same time, LH values were significantly higher in the
PCOS women before as compared to after progesterone
administration.
Serum inhibin A levels before the FSH injection were
significantly lower in the PCOS women than in the con-
trols (Exp 3) (p < 0.05). Treatment with progesterone
suppressed inhibin A levels significantly (Exp 2 as com-
pared to Exp 1) (Figure 2A). After the FSH injection,
inhibin A levels increased significantly in the PCOS
patients but not in the control women (Exp 3, Figure
2A) and the percentage increase was similar before (353
± 81%, Exp 1, p < 0.05) and after progesterone treat-
ment (439 ± 124%, Exp 2, p < 0.01). Serum inhibin A
levels 24 hours after the FSH injection were significantly
lower in the PCOS (Exp 2) than in the controls (Exp 3)
(p < 0.05) (Figure 2A).
Serum inhibin B levels were similar in the PCOS and
controls before FSH injection (Figure 2B). Progesterone
administration did not influence the inhibin B levels.
After the FSH injection, inhibin B levels increased sig-
nificantly in the PCOS women and this was independent
of the progesterone treatment (Exp 1 and Exp 2) (p <
0.05 and p < 0.001 respectively) with no significant dif-
ference between the two experiments; however, in the
controls (Exp 3), inhibin B levels did not increase after
the FSH injection (Figure 2B). Serum inhibin B levels
after the stimulation with FSH were higher, without
reaching significant level, in Exp 1 and Exp 2 than in
Exp 3 (p = 0.07) (Figure 2B).
Discussion
The present results provide new information regarding
the control of inhibin secretion in women with PCOS.
In accordance with previous studies [3,7,10], serum inhi-
bin A levels were significantly lower in women with
PCOS as compared to normally cycling women. Proges-
terone treatment, apart from normalizing LH levels,
further decreased inhibin A levels in the PCOS women.
This indicates that LH may contribute to the control of
inhibin A secretion in PCOS as it has been suggested
for normal women [11]. Nevertheless, based on the spe-
cific pattern of low inhibin A and high LH levels in the
present study, it is likely that PCOS compared to nor-
mal ovaries are less sensitive to endogenous LH stimu-
lus regarding inhibin A secretion.
Our study demonstrates a differential control of inhi-
b i nAs e c r e t i o nb yF S Hi nP C O Sa n di nn o r m a l l y
cycling women, with the ovaries of PCOS women being
more sensitive to FSH stimulus than those of normal
women. Although the relatively small number of women
Figure 1 Serum FSH and LH levels.( A )F S Ha n d( B )L Hl e v e l s
before (white bars) and 24 hours after a single injection of
recombinant FSH (450 IU sc) (black bars) in 10 women with PCOS
and 8 normally cycling women (control). The FSH injection was
given to the women with PCOS twice, i.e. first 15-20 days after a
spontaneous period (before progesterone treatment) and second
after a 20-days treatment with progesterone per os (after
progesterone treatment). The FSH injection was given to the
normally cycling women on cycle day 3. After the FSH injection,
serum FSH levels increased and serum LH levels decreased
significantly. A. *p < 0.05, comparison with corresponding values
before the FSH injection. B. a,b,c,d,e,f,g p < 0.05.
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FSH in the control group, it is possible that this is firstly
related to the methodology used, including the dose and
the route of FSH administration, and secondly to the
time period of observation. In a previous study with the
same number of normal women, in which FSH was not
injected sc but i.v., inhibin A levels increased signifi-
cantly [12] while in another study of a similar sample
size, an increase in inhibin A levels was seen in response
to purified urinary FSH with the FSH dose being of 200
IU i.m. and only after 36 hours from the injection [24].
However, even a higher number of women would not
possibly affect the results, since the small increase in
inhibin A levels (≈33% on average) seen in the control
group is incomparable to the increase in the PCOS
group (≈400%). The increased sensitivity of the PCOS
ovaries to FSH found in our study was independent of
the preceding effect of progesterone in the context of a
simulated luteal phase. This may provide evidence that
it is not the lack of regular menstruation that is respon-
sible for the differential response of inhibin A to FSH in
the PCOS but this response reflects an intrinsic property
of the PCOS ovaries.
The similar circulatory inhibin B concentrations in
both PCOS and normal women have been also found in
previous studies [3-9]. However, unlike inhibin A, pro-
gesterone treatment and concomitant LH levels lowering
had no effect on inhibin B levels in the PCOS women
suggesting that LH is not probably involved in the con-
trol of inhibin B secretion from PCOS ovaries. Relevant
data in the literature on the value of LH are scanty and
conflicting. Although serum inhibin B levels have been
found to be positively correlated to LH levels in vivo
[5], hCG administration suppressed inhibin B secretion
after 24 hours in PCOS women [8], while it was unable
to stimulate inhibin B secretion from polycystic and
normal ovaries in vitro [20].
In the present study it was demonstrated that the
acute stimulation with FSH increased significantly the
serum inhibin B levels in PCOS women something
which is in accordance with previous studies [12,21].
Our experiments, in contrast to previous studies, were
performed in the proximity of a simulated luteal phase
suggesting that the increased sensitivity of the PCOS
ovaries to FSH regarding inhibin B secretion is not
affected by the preceding action of progesterone. It is
therefore likely that, similar to inhibin A, the increased
sensitivity of inhibin B to FSH is an intrinsic property of
the PCOS ovaries. In contrast to other studies that have
shown an increase, the lack of an increase in inhibin B
levels in normal women, following FSH administration,
is in agreement with a previous study [8]. The difference
between them is difficult to explain [9,12,22]. Methodo-
logical differences including the route of FSH adminis-
tration may account for the different results between
the present and the previous studies. Whether the rela-
tively higher age of the control as compared to the
PCOS women contributed to the ovarian unresponsive-
ness to FSH in terms of inhibin A and B secretion is
not very likely, because both basal FSH and inhibin B
levels were comparable in the two groups indicating a
similar potential regarding ovarian reserves. Also,
despite the slightly higher BMI in the PCOS, similar
serum FSH concentrations were achieved in the two
groups following the injection of FSH. In addition, if the
Figure 2 Serum inhibin A and B levels. (A) inhibin A and (B)
inhibin B levels before (white bars) and 24 hours after a single
injection of recombinant FSH (450 IU sc) (black bars) in 10 women
with PCOS and 8 normally cycling women (control). The FSH
injection was given to the women with PCOS twice, i.e. first 15-20
days after a spontaneous period (before progesterone treatment)
and second after a 20-days treatment with progesterone per os
(after progesterone treatment). The FSH injection was given to the
normally cycling women on cycle day 3. After the FSH injection,
serum inhibin A and inhibin B levels increased significantly in the
women with PCOS but not in the control women. A. a,b,c,e,f p <
0.05, d p < 0.001 B. a,b p < 0.05.
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levels [23] one would expect lower levels of this protein
in PCOS as compared to control women, which was not
the case in this study.
In conclusion, our results show for the first time that
in PCOS women normalization of elevated LH levels
with exogenous progesterone decreased inhibin A levels,
while inhibin B levels were unaffected. Besides, following
FSH stimulation PCOS ovaries secreted more inhibin A
and inhibin B compared to normal ovaries and this was
independent of a preceding simulated luteal phase. It is
suggested that the PCOS ovaries may be intrinsically
less sensitive to endogenous LH regarding inhibin A
secretion and more sensitive to exogenous FSH in terms
of both inhibin A and inhibin B secretion.
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